**Edginton 2009** Edginton AN, Ahr G, Willmann S, Stass H. Defining the role of macrophages in local moxifloxacin tissue concentrations using biopsy data and whole-body physiologically based pharmacokinetic modelling. Clin Pharmacokinet. 2009;48(3):181-7. doi: 10.2165/00003088-200948030-00004.

**Grimm 2018** Grimm M, Koziolek M, KÃ¼hn JP, Weitschies W. Interindividual and intraindividual variability of fasted state gastric fluid volume and gastric emptying of water. Eur J Pharm Biopharm. 2018 Jun;127:309-317. doi: 10.1016/j.ejpb.2018.03.002. Epub 2018 Mar 6. PMID: 29522898.

**Kuepfer 2016** Kuepfer L, Niederalt C, Wendl T, Schlender JF, Willmann S, Lippert J, Block M, Eissing T, Teutonico D. Applied Concepts in PBPK Modeling: How to Build a PBPK/PD Model.CPT Pharmacometrics Syst Pharmacol. 2016 Oct;5(10):516-531. doi: 10.1002/psp4.12134. Epub 2016 Oct 19. 	

**Langlois 2005** Langlois MH, Montagut M, Dubost JP, Grellet J, Saux MC. Protonation equilibrium and lipophilicity of moxifloxacin. J Pharm Biomed Anal. 2005 Feb 23;37(2):389-93. doi: 10.1016/j.jpba.2004.10.022. 

**Litjens 2022** Litjens CHC, Verscheijden LFM, Bolwerk C, Greupink R, Koenderink JB, van den Broek PHH, van den Heuvel JJMW, Svensson EM, Boeree MJ, Magis-Escurra C, Hoefsloot W, van Crevel R, van Laarhoven A, van Ingen J, Kuipers S, Ruslami R, Burger DM, Russel FGM, Aarnoutse RE, Te Brake LHM. Prediction of Moxifloxacin Concentrations in Tuberculosis Patient Populations by Physiologically Based Pharmacokinetic Modeling. J Clin Pharmacol. 2022 Mar;62(3):385-396. doi: 10.1002/jcph.1972. 

**PK-Sim Ontogeny Database Version 7.3** ([https://github.com/Open-Systems-Pharmacology/OSPSuite.Documentation/blob/38cf71b384cfc25cfa0ce4d2f3addfd32757e13b/PK-Sim%20Ontogeny%20Database%20Version%207.3.pdf](https://github.com/Open-Systems-Pharmacology/OSPSuite.Documentation/blob/38cf71b384cfc25cfa0ce4d2f3addfd32757e13b/PK-Sim%20Ontogeny%20Database%20Version%207.3.pdf))	

**Schlender 2016** Schlender JF, Meyer M, Thelen K, Krauss M, Willmann S, Eissing T, Jaehde U. Development of a Whole-Body Physiologically Based Pharmacokinetic Approach to Assess the Pharmacokinetics of Drugs in Elderly Individuals. Clin Pharmacokinet. 2016 Dec;55(12):1573-1589. 	

**Siefert 1999** Siefert HM, Domdey-Bette A, Henninger K, Hucke F, Kohlsdorfer C, Stass HH. Pharmacokinetics of the 8-methoxyquinolone, moxifloxacin: a comparison in humans and other mammalian species. J Antimicrob Chemother. 1999 May;43 Suppl B:69-76. doi: 10.1093/jac/43.suppl_2.69. PMID: 10382878.

**Stass and Kabitza 1999** Stass H, Kubitza D. Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man. J Antimicrob Chemother. 1999 May;43 Suppl B:83-90. doi: 10.1093/jac/43.suppl_2.83. 

**Sullivan 1999** Sullivan JT, Woodruff M, Lettieri J, Agarwal V, Krol GJ, Leese PT, Watson S, Heller AH. Pharmacokinetics of a once-daily oral dose of moxifloxacin (Bay 12-8039), a new enantiomerically pure 8-methoxy quinolone. Antimicrob Agents Chemother. 1999 Nov;43(11):2793-7. doi: 10.1128/AAC.43.11.2793.

**U.S. Food and Drug Administration 2000** U.S. Food and Drug Administration. Avelox (moxifloxacin) [biopharmaceutics review]. 2000. Available at: [https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/21-085_Avelox_biopharmr.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/21-085_Avelox_biopharmr.pdf)

**U.S. Food and Drug Administration 2016** U.S. Food and Drug Administration. Moxifloxacin hydrochloride [package insert]. 2016. Available at: [https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021085s063lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021085s063lbl.pdf)

**U.S. Pharmacist 2023** U.S. Pharmacist. Moxifloxacin 20 mg/mL Oral Suspension. 2023. Available at: [https://www.uspharmacist.com/article/moxifloxacin-20-mg-ml-oral-suspension](https://www.uspharmacist.com/article/moxifloxacin-20-mg-ml-oral-suspension)

**Willmann 2019** Willmann S, Frei M, Sutter G, Coboeken K, Wendl T, Eissing T, Lippert J, Stass H. Application of Physiologically-Based and Population Pharmacokinetic Modeling for Dose Finding and Confirmation During the Pediatric Development of Moxifloxacin. CPT Pharmacometrics Syst Pharmacol. 2019 Sep;8(9):654-663. doi: 10.1002/psp4.12446. 
